The human M5 muscarinic acetylcholine receptor (mAChR) has recently emerged as an 33 exciting therapeutic target for treating a range of disorders, including drug addiction. However, 34 a lack of structural information for this receptor subtype has limited further drug development 35 and validation. Here we report a high-resolution crystal structure of the human M5 mAChR 36 bound to the clinically used inverse agonist, tiotropium. This structure allowed for a 37 comparison across all five mAChR family members that revealed important differences in both 38 orthosteric and allosteric sites that could inform the rational design of selective ligands. These 39 structural studies together with chimeric swaps between the extracellular regions of the M2 and 40 M5 mAChR further revealed the structural insight into "kinetic-selectivity", where ligands 41
Introduction 57
The muscarinic acetylcholine (ACh) receptors (mAChRs) are Class A G protein-coupled 58 receptors (GPCRs) that together with the nicotinic acetylcholine receptors facilitate the actions 59 of the neurotransmitter, ACh, throughout the body. The mAChR family comprises five 60 subtypes where M1, M3, and M5 are preferentially coupled to the Gq/11 protein-mediated 61 signalling pathways, and M2 and M4, show preference for Gi/o protein-dependent signalling. 62
Localization studies have revealed that the mAChR subtypes are differentially distributed, with 63 M1, M4, and M5 mAChRs found predominantly in the central nervous system (CNS), where 64 they are essential for normal neuronal function, while M2 and M3 mAChRs are expressed more 65 widely, including in the periphery, where they are involved in cardiovascular as well as gut 66 motility and secretory processes (1) . 67
68
Given the involvement of mAChRs in such a wide range of fundamental physiological 69 processes, they have long been valued as targets for novel therapeutics, in particular the central 70 M1 and M4 mAChRs, which have garnered attention due to their involvement in cognition and 71 memory (2). In contrast, relatively less is known about the M5 mAChR subtype, which 72 represents less than 2% of the total CNS mAChR population (3, 4). Despite its low level of 73 expression, this receptor plays a vital role in the mesolimbic reward pathway due to its presence 74 on dopaminergic neurons of the ventral tegmental area (VTA) (5-8). Additionally, there is a 75 large population of non-neuronal M5 mAChRs located within the endothelium of the cerebral 76 vasculature, suggesting that the receptor may modulate cerebral vasodilatory processes (9, 10). 77
These observations correlate well with phenotypic data from M5 mAChR knockout mice where 78 the cerebral vasculature is constitutively constricted, resulting in decreased cerebral blood flow 79 (11, 12). Additionally, M5 mAChR knockout mice exhibited attenuated reward-seeking 80 behaviour to drugs of addiction, such as cocaine and morphine in self-administration and 81 conditioned place-preference experiments (13-15). Moreover, in recent studies involving rats 82 (16-18), ethanol-seeking behaviour and oxycodone self-administration were attenuated by the 83 selective M5 mAChR negative allosteric modulator (NAM) ML375 (19) . From these studies, 84
the M5 mAChR has emerged as a potential target for the treatment of drug addiction. 85 86 Despite such promising data, further study of the M5 mAChR has been hindered by a lack of 87 selective small molecule tool compounds. Designing conventional small molecule ligands that 88 target the orthosteric ACh binding site of individual mAChR subtypes has been challenging 89 due to the highly conserved sequence homology of the mAChR orthosteric site residues (1) , 90 and in part due to a lack of detailed structural information for all five receptor subtypes. While 91 structures of the M1-M4 mAChRs have been previously determined, there are no available 92 structures for the M5 mAChR. Therefore, to provide a complete structural comparison of all 93 five family members and to gain insight into ligand binding we determined a high-resolution 94 crystal structure of the M5 mAChR. 95
96

Results
97
Crystallization and determination of the M5 mAChR structure. 98
To determine the M5 mAChR structure we designed a construct where residues 225-430 of 99 intracellular loop 3 were removed and replaced with a T4 lysozyme (T4L) fusion protein. Additionally, to promote crystallization, the first 20 N-terminal amino acids were cleaved by a 101
Tobacco Etch Virus (TEV) protease site engineered into the receptor (Supplementary Figure  102 1a). The inverse agonist, tiotropium, was used to stabilize the inactive state as it has a slow 103 dissociation rate at the M5 mAChR (20), and was also used in the determination of the M1, M3, 104 and M4 mAChR structures (21, 22). The M5-T4L•tiotropium complex was crystallized in 105 lipidic cubic phase (LCP), and crystals were obtained within 1-2 days; however, despite many 106 rounds of optimization, diffraction was limited to 7 Å. To improve the resolution we built upon 107 a study from Yasuda et al. (23) that predicted that mutation of the amino acid at position 3.39 108 (numbered according to Ballesteros-Weinstein (24)) to Arg would create a thermostabilized 109 receptor by promoting an ionic bond between this residue and the highly conserved D 2.50 110 residue. Recently, the same S 3.39 R mutation was applied to the M2 mAChR resulting in a series 111 of higher resolution structures (25). Although introduction of the S117 3.39 R mutation resulted 112 in a construct that binds the antagonists NMS or tiotropium with a slightly reduced affinity 113 relative to the WT M5 mAChR, the effect of the mutation on reducing ACh affinity was 114 substantially more pronounced ( Supplementary Figure 1b -e), consistent with the ability of the 115 construct to favour an inactive over an active state. Similar differential effects on antagonist 116 versus agonist affinity were previously observed for S 3.39 R at the M2 mAChR (25). Notably, 117 introduction of the S117 3.39 R mutation increased our M5 mAChR yields during purification and 118 resulted in crystals that diffracted to a resolution of 3.4 Å. Data were collected from 119 approximately 130 crystals, and the structure was determined by molecular replacement using 120 the M3 structure (PDB: 4U15) and an ensemble of T4L structures as templates ( Figure 1a , 121 Supplementary Table 1) . modulators. The structure from 4B-C7/3-phth was the most resolved of all the datasets and is 126 used in all further comparisons (Supplementary Table 1 ). 127
128
To investigate the nature of NAMs binding to the M5 mAChR, we attempted to obtain co-129 crystal structures. Given that the bis-ammonium alkane type ligands tend to have higher 130 affinities for the M5 mAChR than the prototypical modulator, gallamine (26), we tried to obtain 131 a ternary complex structure of the M5 mAChR with tiotropium and several bis-ammonium 132 alkane ligands ( Figure 1b ). We initially used the modulator, 4B-C7/3-phth, which resulted in 133 crystals that grew to a much larger size and diffracted to a resolution of 2.55 Å ( Figure 1 Supplementary Table 2 ) and detectability by X-rays. The first modification added 144 two bromine atoms (4P-C7/3-bromo-phth) to increase the size of the pthalamide groups (29), 145 and the second modification rigidified the flexible 7-carbon linker with an aromatic 146 hydrocarbon (4P-aryl-C7/3-bromo-phth). Both ligands displayed an increased affinity for the 147 M5 mAChR versus 4B-C7/3-phth, but had a slightly reduced affinity in relation to the parent 148 compound (4P-C7/3-phth) when assayed for NAM activity in inhibiting [ 3 H]NMS radioligand 149 binding ( Supplementary Figure 3a , Supplementary Table 2 ). Like 4B-C7/3-phth, the addition 150 of either 4P-C7/3-bromo-phth or 4P-aryl-C7/3-bromo-phth to purified M5 mAChR and 151 reconstitution into LCP yielded crystals that diffracted to a higher resolution (Supplementary 152 Table 1 ). A full data set for 4P-aryl-C7/3-bromo-phth was collected at wavelength of 0.92 Å to 153 maximize the anomalous Br signal in a single wavelength anomalous diffraction experiment, 154 however, no such signal was detected, suggesting that 4P-aryl-C7/3-bromo-phth was not 155 present in the structure. Since the structure was solved by merging a large number of datasets, 156 there is possibility that the Br signal for the NAM would be averaged out if NAM occupancy 157 is low. However, inspection of different datasets did not indicate that this was the case. 158
159
As an alternate strategy, we attempted to determine a co-crystal structure with the structurally 160 diverse M5 mAChR selective NAM, ML375 (19) . In comparison to the bis-ammonium ligands, 161 the addition of ML375 resulted in a slightly lower resolution structure (2.7 Å, Supplementary 162 Table 1 ) and, as was the case with the bis-ammonium NAMs, we were not able to assign 163 ML375 into any electron density. Comparison of all M5 mAChR structures showed that they 164 were nearly identical, with root mean square deviation values of 0.09-0.22 Å. The higher 165 resolution 2.55 Å M5•tiotropium (4B-C7/3-phth) structure was used for further comparison, as 166 this was the best resolved and modelled structure. 167 168
Family-wide comparison of all mAChR subtypes. 169
The solution of the M5 mAChR structure allows the first complete subtype-wide comparison 170 of this important GPCR family. The structure of the M5 mAChR is similar to the previously 171 determined structures of the M1-M4 mAChR subtypes (21, 22, 30) with a root mean squared 172 deviation of 0.5-0.8 Å (Figure 2a ) for the seven-transmembrane domain across all subtypes. 173
The five mAChR subtypes are most similar in the orthosteric binding site, which is the most 174 conserved region of the receptor. The fact that our M5 mAChR structure was obtained in 175 complex with the same ligand (tiotropium), as the M1, M3 and M4 mAChR structures, allowed 176 for specific, detailed comparison of residues lining this orthosteric binding site (Figures 2b,c) .
7
This comparison demonstrated that the residues within the orthosteric pocket are absolutely 178 conserved between the receptors. Although there is no tiotropium bound M2 mAChR structure, 179
there are now six different inactive state M2 mAChR structures, which include structures bound 180 with the non-selective ligands QNB and NMS, and the M2 mAChR selective ligand, AF-181 DX384 (25). The 2.3 Å M2•NMS structure is most similar to the tiotropium bound mAChR 182 structures, though residues Y 3.33 and Y 7.39 of the "tyrosine lid" (Y 3.33 , Y 6.51 , and Y 7.39 ) are 183 positioned in a distinct conformation in comparison to the tiotropium bound structures. These 
mAChRs. 220
An alternative strategy to generating selective ligands is to target non-conserved allosteric sites 221 (32). This has been extensively explored for the mAChR family where a palette of both positive 222 and negative allosteric modulators has been identified (33, 34). Structural and mutagenesis 223 studies have established that many of these ligands bind to a "common" allosteric site that is 224 located above the orthosteric site and within an ECV (Figure 3 , Supplementary Figure 4 
) (35). 225
In fact, the M5 mAChR has often served as model system for early research into understanding 226 the binding mode and mechanism of selectivity for prototypical modulators, such as the bis-227 ammonium alkane ligands (Figure 1b ), that have higher sensitivity for modulating the M2 228 mAChR and lower sensitivity for the M5 mAChR (26, 36-39). These studies identified non-229 conserved residues in ECL2 (P179 -4 , E182 -1 , and Q184 +1 ; superscript indicates the position of 230 ECL2 residues relative to the conserved Cys in ECL2) and TM7 (V474 7.32 and H484 7.36 ) as 231 residues that can account for M2/M5 subtype selectivity. Comparison of the ECV between the 232 9 M2 and M5 mAChRs confirm differences in the orientations and positions of these residues that 233 could mediate the selectivity. Namely, P179 -4 in ECL2 restricts the position of E182 -1 forcing 234 the residue into the ECV near Q184 +1 . Residue Q184 +1 , which is a F/Y residue for the M1-M4 235 mAChRs subtypes, is a key residue for the activity of many allosteric modulators. Other major 236 differences between the M2/M5 ECVs are in the positions of non-conserved residues lining the 237 top of TM6 starting from S465 6.58 across ECL3 and down to residue H478 7.36 in TM7. At the 238 M5 mAChR these residues are bulkier and point more inward constricting the overall size of 239 the ECV (Figure 3) . Residues are numbered based on the M5 mAChR, with residues in ECL2 numbered relative to 246 the conserved cysteine in ECL2, which is shown as a yellow sphere. 247 248
Role of the M5 and M2 mAChR ECL regions in orthosteric and allosteric ligand binding. 249
The effect of ECL regions on orthosteric ligand access and egress has significant biological 250 and clinical relevance (40). Therefore, to investigate the role of the ECLs on modulating the 251 slower dissociation kinetics of the M5 mAChR in comparison to the M2 mAChR, we designed 252 full ECL1, ECL2, and/or ECL3 chimeric swaps between the two subtypes ( Figure 4) . The ECL 253 chimeras had similar levels of expression and binding of [ 3 H]NMS to wild type receptors 254 (Supplementary Table 3 ). As previously noted, the M2 mAChR has a shorter half-life for 255
[ 3 H]NMS dissociation in comparison to the M5 mAChR ( Figure 2f) particularly at the M5 mAChR (Figure 4 , Supplementary Table 4 ). A possible structural 260 explanation for this observation could be that R95 ECL1 , which is a conserved Tyr residue at the 261 M1-M4 subtypes, is capable of forming an ionic bond with either the M5 ECL2 residue, D181 -262 2 , or in the case of the M2 ECL1 chimera residue D173 -3 (Figure 3, Supplementary Figure 4) . 263
Such an interaction could tether ECL1 and ECL2 limiting their overall dynamics and thus 264 reduce rates of orthosteric ligand dissociation. It is important to note that R95 ECL1 is involved 265 in an ionic interaction mediated through the crystal lattice with a neighbouring T4L molecule 266
( Supplementary Figure 2d-f ), and as a result it does not directly interact with D181 -2 in the M5 267 mAChR structure though it is well positioned to do so. 268
269
A hallmark feature of an allosteric ligand that modulates orthosteric ligand affinity is the ability 270 to either increase or decrease the rate of dissociation of an orthosteric ligand. To examine the 271 effect of allosteric modulators on NMS dissociation across the M5 and M2 ECL chimeras, we 272 used the bis-ammonium alkane ligand 4P-C7/3-phth, which had been previously studied at the 273 M2 mAChR and had high affinity for the M5 mAChR ( Supplementary Table 2 ), or the M5 274 selective modulator ML375 (19, 27). In the presence of ML375, [ 3 H]NMS dissociation was 275 reduced at the M5 mAChR and had no effect at the M2 mAChR, whereas the addition of 4P-276 C7/3-phth reduced radioligand dissociation at the M2 mAChR but not at the M5 mAChR ( Figure  277 4, Supplementary Table 4 ). The ECL1 and ECL3 chimeric swaps had little effect on the activity 278 of ML375 for either receptor subtype, and slightly increased the activity of 4P-C7/3-phth at the 279 M5 mAChR. For the ECL2 chimeras, there was no effect on activity of ML375. However, there 280 was a loss of 4P-C7/3-phth activity at the M2 mAChR and a corresponding gain of activity at 281 the M5 mAChR. These results are in line with previous studies and highlight the importance of 282 residues in ECL2, particularly M2-Y177 and M5-E184, on modulating the activity of bis-283 ammonium alkane ligands. Interestingly, when all three ECLs were swapped, the resulting M2 284 and M5 chimeric constructs functioned more like their swapped receptor counterpart. That is, 285
for the M2-M5-all-ECL construct, 4P-C7/3-phth had little effect, and although ML375 did not 286
retard [ 3 H]NMS dissociation, it slightly increased the rate of [ 3 H]NMS dissociation suggesting 287
an allosteric mode of action (Figure 4 , Supplementary Table 4 ). Conversely, for the M5-M2-288 all-ECL construct, 4P-C7/3-phth retarded radioligand dissociation and, surprisingly, ML375 289 had no effect. While none of the chimeric constructs ever fully switched the basal dissociation 290 rate of [ 3 H]NMS or ML375 activity to that observed for the corresponding WT constructs, the 291 data nonetheless suggest that the ECL regions modulate the overall conformation of mAChRs 292 and directly influence the dissociation of ligands from the orthosteric site. 293 294 295
Figure 4. [ 3 H]NMS binding dissociation kinetic studies of chimeric swaps between the 296
ECLs of the M2 and M5 mAChRs. (a) Cartoons and (b) amino acid sequence composition 297
for the M2 and M5 ECL chimeras used in this study, with conserved residues noted by an 298 asterix. (c) [ 3 H]NMS re-association was prevented by the addition of 10 µM atropine, and 299 radioligand dissociation was monitored in the absence or presence of 10 µM ML375 or 10 µM 300 4P-C7/3-phth. Data points represent the mean ± S.E.M. of three or more independent 301 experiments performed in duplicate. Quantitative parameters derived from this experiment are 302 listed in Supplementary Table 4 . 303 304
Discussion 305
Individual mAChR subtypes have long been pursued as drug targets for a range of CNS 306 disorders, and recent studies have begun to validate the M5 mAChR as a novel target for the 307 treatment of drug addiction (4, 41). In this study, we have determined a high-resolution crystal 308 structure of the M5 mAChR, thus allowing the first subtype-wide comparison for any aminergic 309 GPCR subfamily. Introduction of the inactive state stabilizing mutation S117 3.39 R, which was 310 recently used to stabilize the M2 mAChR (25), was crucial to obtaining well-diffracting crystals 311 and suggests that this mutation could be applied to aid the determination of inactive state 312 structures for other related GPCRs. We further improved the resolution of the M5 mAChR 313 structure by adding allosteric modulators to the purified protein prior to crystallization. Despite 314 the consistent increase in resolution that each of the allosteric modulator provided, we were 315 not able to model any of the modulators into electron density. From a pharmacological 316 perspective, a lack of modulator binding is not surprising, as all of the modulators tested in this 317 study showed strong negative cooperativity with tiotropium ( Supplementary Figure 3b) . 318
Nevertheless, it is still paradoxical that the addition of an allosteric modulator can clearly 319 improve receptor crystallization and diffraction, though not be visible in any resulting 320 structures. This phenomenon has been noted at other GPCRs, such as the M2 mAChR that was 321 crystallized in the presence of the modulator, alcuronium, and the CC chemokine receptor 2A 322 that was crystallized in the presence of the modulator, AZD-6942, but where neither modulator 323 could be observed in the resulting structures (25, 42) . 324
325
Comparison of all five mAChR structures further confirms the well conserved transmembrane 326 core and orthosteric binding site that has made the discovery of highly selective drugs for these 327 receptor subtypes incredibly challenging. The most apparent structural differences between the 328 mAChR subtypes is in the ECL regions. Though these differences are generally quite subtle 329 they are important because they open up the possibility for designing selective molecules in a 330 way that has not previously been possible ( Supplementary Figure 4) . For example, a recent 331 crystal structure of the M2 mAChR bound to the M2-selective antagonist AF-DX384 revealed 332 that selectivity is mediated by differential interactions between the ligand and residues in 333 ECL2, which lead to an outward displacement in ECL2 and the top of TM5 (Figure 2d) (25) . 334
Likewise, by utilizing knowledge of a single amino acid difference in ECL2 between the M2 335 and M3 mAChRs, molecular docking and structure-based design led to the discovery of a new 336 M3-selective antagonist with 100-fold selectivity over the M2 mAChR (43). These results are 337 similar to the structure-based design of biased ligands targeting the D2 dopamine receptor that 338 were designed by utilizing specific amino acid-ligand contacts in ECL2 and TM5 (44). Taken 339 together, these findings indicate that the differential targeting of ECL residues may be a path 340 forward for creating selective mAChR ligands. This is well supported by the fact that many 341 mAChR-selective allosteric modulators interact with the ECL regions (27, 35), and suggest 342 13 that designing orthosteric ligands linked to allosteric pharmacophores, known as bitopic 343 ligands, is a potential strategy for future structure-based drug design. 344
345
Drug discovery has typically focused on optimizing ligand affinity and selectivity. However, 346
it is now apparent that binding kinetics are just as important (40, (45) (46) (47) . This is illustrated two 347 ways with the drug tiotropium as a pertinent example. First, tiotropium has slow rate of 348 dissociation from the M3 mAChR, which is a key feature of the drug that allows for a once 349 daily dosing for the treatment of chronic obstructive pulmonary disease (48). Second, though 350 tiotropium has the same equilibrium binding affinity for the M3 and M2 mAChRs, it exhibits 351 kinetic selectivity for the M3 over M2 mAChR, by having substantially different rates of 352 dissociation. This kinetic selectivity over the M2 mAChR is postulated to be due to differences 353 in the electrostatics and dynamics of the ECL region (48). The M5 mAChR is similar to the M3 354 mAChR with respect to having slow rates of orthosteric ligand dissociation (20), and data from 355 our M2/M5 ECL chimeras support the idea of the ECL regions mediating kinetic selectivity as 356
[ 3 H]NMS dissociation was switched between the M2 and M5 mAChRs (Figure 4) . Notably, 357 none of the combined ECL chimeras could ever fully switch the dissociation kinetics between 358
subtypes, suggesting that other mechanisms are operative such as the global conformation of 359 the ECLs. Our results also highlight the importance of the ECL regions on conferring 360 sensitivity to allosteric modulators across different subtypes. By swapping out the entire ECL 361 region between the M2 and M5 mAChRs we were able to completely alter the sensitivity of a 362 modulator that is selective for the M2 versus the M5 mAChR and vice versa. These results 363 support the importance of the ECL region for mediating ligand selectivity. 364
365
In summary, our reported M5 mAChR crystal structure has allowed for the comparison of all 366 five mAChR subtypes and has revealed that subtle differences in the ECL regions are a major 367 determinant in ligand selectivity, regardless of the ligand being orthosteric or allosteric. As the 368 M1, M4, and M5 mAChRs continue to emerge as exciting drug targets for the treatment of CNS 369 disorders, it will be important to understand both the structural and dynamic differences 370 between all five mAChR subtypes in order to aid design of safer and more effective small-371 molecule therapeutics. ( Supplementary Figure 1 ). In addition, to stabilize the inactive state we introduced the mutation 379 Crystals appeared in the first 24 hours and grew to full size in the following 1-2 days. The best 422 diffracting crystals grew in 100 mM DL-Malic acid pH 6.0, 220-280 mM ammonium tartrate 423 dibasic and 37-41% PEG 400. For the data collection, whole drops were harvested using mesh 424 grid loops (Mitegen) and flash frozen in liquid nitrogen. 425 X-ray diffraction data were collected at the SPring-8 (Japan) beamline BL32XU (49) 426 and the MX2 beamline at the Australian Synchrotron (50) . Diffraction data at SPring-8 was 427 collected using the automatic data-collection system ZOO (51). Diffraction data was processed 428 using KAMO (52) with XDS (53). The structure was solved using molecular replacement with 429 M3-mT4L (4U15) as a search model for the receptor and an ensemble of T4L molecules for 430 T4L. Structure refinement was performed with Phenix (54), and the models were validated 431 with MolProbity (55). Structure figures were prepared with PyMol. was removed by inverting the plate and followed by 3 washes with ice-cold 0.9% sodium 472 chloride. Bound radioactivity was assessed by liquid scintillation using Optiphase Supermix 473 (100 µL) and counting on a MicroBeta2 Plate Counter. 474
